|
1
|
Huang L, Perrault C, Coelho-Martins J, Hu
C, Dulong C, Varna M, Liu J, Jin J, Soria C, Cazin L, et al:
Induction of acquired drug resistance in endothelial cells and its
involvement in anticancer therapy. J Hematol Oncol. 6:492013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang L, Hu C, Di Benedetto M, Varin R,
Liu J, Wang L, Vannier JP, Jin J, Janin A, Lu H and Li H: Induction
of multiple drug resistance in HMEC-1 endothelial cells after
long-term exposure to sunitinib. Onco Targets Ther. 7:2249–2255.
2014.
|
|
3
|
Huang L, Hu C, Di Benedetto M, Varin R,
Liu J, Jin J, Wang L, Vannier JP, Janin A, Lu H and Li H:
Cross-drug resistance to sunitinib induced by doxorubicin in
endothelial cells. Oncol Lett. 9:1287–1292. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Naito H, Wakabayashi T, Kidoya H,
Muramatsu F, Takara K, Eino D, Yamane K, Iba T and Takakura N:
Endothelial side population cells contribute to tumor angiogenesis
and antiangiogenic drug resistance. Cancer Res. 76:3200–3210. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weis SM and Cheresh DA: Tumor
angiogenesis: Molecular pathways and therapeutic targets. Nat Med.
17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mendel DB, Laird AD, Xin X, Louie SG,
Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et
al: In vivo antitumor activity of SU11248, a novel tyrosine kinase
inhibitor targeting vascular endothelial growth factor and
platelet-derived growth factor receptors: Determination of a
pharmacokinetic/pharmaco-dynamic relationship. Clin Cancer Res.
9:327–337. 2003.PubMed/NCBI
|
|
7
|
Jayson GC, Kerbel R, Ellis LM and Harris
AL: Antiangiogenic therapy in oncology: Current status and future
directions. Lancet. 388:518–529. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar
|
|
9
|
Huijbers EJ, van Beijnum JR, Thijssen VL,
Sabrkhany S, Nowak-Sliwinska P and Griffioen AW: Role of the tumor
stroma in resistance to anti-angiogenic therapy. Drug Resist Updat.
25:26–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gu Y, Lu H, Boisson-Vidal C, Li H,
Bousquet G, Janin A and Di Benedetto M: Resistance to
anti-angiogenic therapy: A clinical and scientific current issue.
Med Sci (Paris). 32:370–377. 2016.In French. View Article : Google Scholar
|
|
11
|
Nunes T, Hamdan D, Leboeuf C, El
Bouchtaoui M, Gapihan G, Nguyen TT, Meles S, Angeli E, Ratajczak P,
Lu H, et al: Targeting cancer stem cells to overcome
chemoresistance. Int J Mol Sci. 19:E40362018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
MacIntyre AC and Cutler DJ: The potential
role of lysosomes in tissue distribution of weak bases. Biopharm
Drug Dispos. 9:513–526. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duvvuri M and Krise JP: Intracellular drug
sequestration events associated with the emergence of multidrug
resistance: A mechanistic review. Front Biosci. 10:1499–1509. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kazmi F, Hensley T, Pope C, Funk RS,
Loewen GJ, Buckley DB and Parkinson A: Lysosomal sequestration
(trapping) of lipophilic amine (cationic amphiphilic) drugs in
immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos.
41:897–905. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gotink KJ, Broxterman HJ, Labots M, de
Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters
RJ, Jansen G, et al: Lysosomal sequestration of sunitinib: A novel
mechanism of drug resistance. Clin Cancer Res. 17:7337–7346. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamagishi T, Sahni S, Sharp DM, Arvind A,
Jansson PJ and Richardson DR: P-glycoprotein mediates drug
resistance via a novel mechanism involving lysosomal sequestration.
J Biol Chem. 288:31761–31771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhitomirsky B and Assaraf YG: Lysosomal
sequestration of hydrophobic weak base chemotherapeutics triggers
lysosomal biogenesis and lysosome-dependent cancer multidrug
resistance. Oncotarget. 6:1143–1156. 2015. View Article : Google Scholar :
|
|
18
|
Chapuy B, Koch R, Radunski U, Corsham S,
Cheong N, Inagaki N, Ban N, Wenzel D, Reinhardt D, Zapf A, et al:
Intracellular ABC transporter A3 confers multidrug resistance in
leukemia cells by lysosomal drug sequestration. Leukemia.
22:1576–1586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gotink KJ, Broxterman HJ, Honeywell RJ,
Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters
GJ, Pili R and Verheul HM: Acquired tumor cell resistance to
sunitinib causes resistance in a HT-29 human colon cancer xenograft
mouse model without affecting sunitinib biodistribution or the
tumor microvasculature. Oncoscience. 1:844–853. 2014. View Article : Google Scholar
|
|
20
|
Santoni M, Amantini C, Morelli MB,
Liberati S, Farfariello V, Nabissi M, Bonfili L, Eleuteri AM,
Mozzicafreddo M, Burattini L, et al: Pazopanib and sunitinib
trigger autophagic and non-autophagic death of bladder tumour
cells. Br J Cancer. 109:1040–1050. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ikeda T, Ishii KA, Saito Y, Miura M,
Otagiri A, Kawakami Y, Shimano H, Hara H and Takekoshi K:
Inhibition of autophagy enhances sunitinib-induced cytotoxicity in
rat pheochromocytoma PC12 cells. J Pharmacol Sci. 121:67–73. 2013.
View Article : Google Scholar
|
|
22
|
Abdel-Aziz AK, Shouman S, El-Demerdash E,
Elgendy M and Abdel-Naim AB: Chloroquine synergizes sunitinib
cytotoxicity via modulating autophagic, apoptotic and angiogenic
machineries. Chem Biol Interact. 217:28–40. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Giuliano S, Cormerais Y, Dufies M, Grépin
R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S,
Mazure NM, et al: Resistance to sunitinib in renal clear cell
carcinoma results from sequestration in lysosomes and inhibition of
the autophagic flux. Autophagy. 11:1891–1904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maiuri MC, Zalckvar E, Kimchi A and
Kroemer G: Self-eating and self-killing: Crosstalk between
autophagy and apoptosis. Nat Rev Mol Cell Biol. 8:741–752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Turco E and Martens S: Insights into
autophagosome biogenesis from in vitro reconstitutions. J Struct
Biol. 196:29–36. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Antonioli M, Di Rienzo M, Piacentini M and
Fimia GM: Emerging mechanisms in initiating and terminating
autophagy. Trends Biochem Sci. 42:28–41. 2017. View Article : Google Scholar
|
|
27
|
Rubinsztein DC, Codogno P and Levine B:
Autophagy modulation as a potential therapeutic target for diverse
diseases. Nat Rev Drug Discov. 11:709–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yoshida GJ: Therapeutic strategies of drug
repositioning targeting autophagy to induce cancer cell death: From
pathophysiology to treatment. J Hematol Oncol. 10:672017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pu J, Guardia CM, Keren-Kaplan T and
Bonifacino JS: Mechanisms and functions of lysosome positioning. J
Cell Sci. 129:4329–4339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoshii SR and Mizushima N: Monitoring and
measuring autophagy. Int J Mol Sci. 18:E18652017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eskelinen EL: Roles of LAMP-1 and LAMP-2
in lysosome biogenesis and autophagy. Mol Aspects Med. 27:495–502.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gagliardi S, Rees M and Farina C:
Chemistry and structure activity relationships of bafilomycin A1, a
potent and selective inhibitor of the vacuolar H+-ATPase. Curr Med
Chem. 6:1197–1212. 1999.PubMed/NCBI
|
|
33
|
Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr
M, Hijlkema KJ, Coppes RP, Engedal N, Mari M and Reggiori F:
Chloroquine inhibits autophagic flux by decreasing
autophagosome-lysosome fusion. Autophagy. 14:1435–1455. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Heuser J: Changes in lysosome shape and
distribution correlated with changes in cytoplasmic pH. J Cell
Biol. 108:855–864. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Galluzzi L, Baehrecke EH, Ballabio A, Boya
P, Bravo-San Pedro JM, Cecconi F, Choi AM, Chu CT, Codogno P,
Colombo MI, et al: Molecular definitions of autophagy and related
processes. EMBO J. 36:1811–1836. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maes H, Rubio N, Garg AD and Agostinis P:
Autophagy: Shaping the tumor microenvironment and therapeutic
response. Trends Mol Med. 19:428–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maes H, Kuchnio A, Peric A, Moens S, Nys
K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, et
al: Tumor vessel normalization by chloroquine independent of
autophagy. Cancer Cell. 26:190–206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang D, Ding Y, Li Y, Luo WM, Zhang ZF,
Snider J, Vandenbeldt K, Qian CN and Teh BT: Sunitinib acts
primarily on tumor endothelium rather than tumor cells to inhibit
the growth of renal cell carcinoma. Cancer Res. 70:1053–1062. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Moslehi JJ: Cardiovascular toxic effects
of targeted cancer therapies. N Engl J Med. 375:1457–1467. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bretagne M, Boudou-Rouquette P, Huillard
O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J,
Tlemsani C, Cessot A, Cabanes L, et al: Tyrosine kinase inhibiting
the VEGF pathway and elderly people: Tolerance, pre-treatment
assessment and side effects management. Bull Cancer. 103:259–272.
2016.In French. View Article : Google Scholar : PubMed/NCBI
|
